Giredestrant

Breast Carcinoma

MedSIRSmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Trastuzumab SWOG Cancer Research Network	Phase 4	BBB
Tamoxifen Dartmouth-Hitchcock Medical Center	Phase 4	BBB
Zoledronate Washington University School of Medicine	Phase 4	BBB
Pertuzumab SWOG Cancer Research Network	Phase 3	BBB
Trastuzumab Deruxtecan SWOG Cancer Research Network	Phase 4	BBB

View all 50 →

Same molecule, other indications

Giredestrant is also rated in:

estrogen-receptor positive breast cancerActive

BB

Indicative · Phase 3

70 / 100

breast cancerActive

B

Indicative · Phase 3

63 / 100

ovarian cancerActive

CC

Indicative · Phase 2

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.